{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:17:31Z","timestamp":1778692651534,"version":"3.51.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Herpes zoster severely impacts patients\u2019 quality of life and therapeutic results. This research utilized data from the FDA Adverse Event Reporting System (FAERS) to examine the prevalence and attributes of drug-induced herpes zoster.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed FAERS reports about zoster from Q1 2004 to Q3 2024 and developed a list of possible pathogenic agents. Ranked the 30 medicines with the greatest incidence of reported herpes zoster cases. Statistical disproportionality analysis was employed to identify an elevated reporting frequency of herpes zoster linked to a particular medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Herpes zoster was referenced in 50,164 FAERS reports from 2004 to 2024. The majority of the implicated drugs were immunosuppressants. Anifrolumab exhibited the greatest ROR and PRR ratings among the drugs evaluated. Furthermore, rozanolixizumab, tozinameran, elapegademase, and other medications not indicated for inducing herpes zoster were recognized, underscoring the necessity for increased clinical vigilance and awareness. Nonetheless, these correlations should be regarded with caution, as they do not establish a direct causative relationship.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study underscores the need of pharmacovigilance in recognizing and comprehending drug-induced herpes zoster. Additional research is required to validate these findings and to design strategies for risk management and reduction to enhance treatment outcomes in patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1565480","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T07:19:15Z","timestamp":1742973555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiali","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1161849","DOI":"10.3389\/fimmu.2023.1161849","article-title":"The value of interferon \u0392 in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review","volume":"14","author":"Bellucci","year":"2023","journal-title":"Front. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00198-003-1399-y","article-title":"Pharmacovigilance study of alendronate in england","volume":"14","author":"Biswas","year":"2003","journal-title":"Osteoporos. Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.rdc.2016.09.010","article-title":"Incidence and prevention of herpes zoster reactivation in patients with autoimmune diseases","volume":"43","author":"Chakravarty","year":"2017","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"B5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12879-017-2198-y","article-title":"Looking back to move forward: a twenty-year audit of herpes zoster in asia-pacific","volume":"17","author":"Chen","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet London, Engl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv."},{"key":"B9","doi-asserted-by":"publisher","first-page":"adv00648","DOI":"10.2340\/actadv.v102.175","article-title":"Global risk of bacterial skin infections and herpesviridae infections with ustekinumab, secukinumab, and tumour necrosis factor-alpha inhibitors: spontaneous reports of adverse drug reactions from the world health organization pharmacovigilance center","volume":"102","author":"Davidson","year":"2022","journal-title":"Acta dermato-venereologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40264-012-0006-6","article-title":"Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database","volume":"36","author":"Fuzier","year":"2013","journal-title":"Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/1346-8138.17245","article-title":"Systemic therapy for psoriasis and the risk of cutaneous infections","volume":"51","author":"Higashi","year":"2024","journal-title":"J. dermatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jaad.2015.12.059","article-title":"Immunosuppressive medication use and risk of herpes zoster (hz) in patients with systemic lupus erythematosus (sle): a nationwide case-control study","volume":"75","author":"Hu","year":"2016","journal-title":"J. Am. Acad. Dermatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13075-022-02871-1","article-title":"Incident and recurrent herpes zoster for first-line bdmard and tsdmard users in seropositive rheumatoid arthritis patients: a nationwide cohort study","volume":"24","author":"Jeong","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/cid\/ciw296","article-title":"Increasing incidence of herpes zoster over a 60-year period from a population-based study","volume":"63","author":"Kawai","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40744-021-00352-6","article-title":"Real-world safety and effectiveness of golimumab in rheumatic diseases: post-marketing surveillance in korea","volume":"8","author":"Kim","year":"2021","journal-title":"Rheumatology Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12883-019-1354-y","article-title":"An update on peginterferon beta-1a management in multiple sclerosis: results from an interdisciplinary board of German and Austrian neurologists and dermatologists","volume":"19","author":"Kolb-M\u00e4urer","year":"2019","journal-title":"BMC Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/14740338.2023.2278700","article-title":"Drug-induced hypoglycemia: a disproportionality analysis of the faers database","volume":"23","author":"Li","year":"2024","journal-title":"Expert Opin. drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40264-015-0351-3","article-title":"An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies","volume":"39","author":"Maci\u00e1-Mart\u00ednez","year":"2016","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"Jama"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","article-title":"Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting","volume":"80","author":"Miyazaki","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/0961203320923739","article-title":"Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies","volume":"29","author":"Mok","year":"2020","journal-title":"Lupus"},{"key":"B24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14740338.2019.1577817","article-title":"Update upon the infection risk in patients receiving tnf alpha inhibitors","volume":"18","author":"Murdaca","year":"2019","journal-title":"Expert Opin. drug Saf."},{"key":"B25","article-title":"Ab0643 il-1 blockage with anakinra in gout patients","volume-title":"Scoping review of the published literatur","author":"Navarro","year":"2021"},{"key":"B26","first-page":"S40","article-title":"Infected herpes zoster in a chronic lymphocytic leukemia patient treated with ibrutinib","volume":"85","author":"Okay","year":"2019"},{"key":"B27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annepidem.2005.12.002","article-title":"Gender as an independent risk factor for herpes zoster: a population-based prospective study","volume":"16","author":"Opstelten","year":"2006","journal-title":"Ann. Epidemiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1016\/j.mayocp.2021.05.029","article-title":"Corticosteroid use and risk of herpes zoster in a population-based cohort","volume":"96","author":"Qian","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the fda adverse event reporting system","volume":"14","author":"Raschi","year":"2019","journal-title":"Target Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","article-title":"Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic dmard treatment: data from the German rabbit register","volume":"81","author":"Redeker","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"20552173241238632","DOI":"10.1177\/20552173241238632","article-title":"Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: final results from the plegridy observational program","volume":"10","author":"Salvetti","year":"2024","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.2005.03.7903","article-title":"Phase ii multicenter study of arsenic trioxide in patients with myelodysplastic syndromes","volume":"24","author":"Schiller","year":"2006","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2217\/imt-2021-0333","article-title":"Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors","volume":"14","author":"Serra","year":"2022","journal-title":"Immunotherapy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"999704","DOI":"10.3389\/fimmu.2022.999704","article-title":"Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials","volume":"13","author":"Steiger","year":"2022","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"665559","DOI":"10.3389\/fmed.2021.665559","article-title":"Risk of herpes zoster among psoriasis patients taking biologics: a network meta-analysis of cohort studies","volume":"8","author":"Tang","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jbspin.2016.04.001","article-title":"Herpes zoster: risk and prevention during immunomodulating therapy","volume":"84","author":"Tran","year":"2017","journal-title":"Jt. Bone Spine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/infdis\/jiz652","article-title":"The epidemiology of herpes zoster in immunocompetent, unvaccinated adults \u226550 Years old: incidence, complications, hospitalization, mortality, and recurrence","volume":"222","author":"Tseng","year":"2020","journal-title":"J. Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijid.2021.08.048","article-title":"Herpes zoster after covid vaccination","volume":"111","author":"van Dam","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: a systematic review of epidemiological studies","volume":"155","author":"van Hecke","year":"2014","journal-title":"Pain"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with jak inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.13107\/jocr.2250-0685.1272","article-title":"Delayed diagnosis of herpes zoster infection due tolong-term pregabalin treatment for lumbar spinal canal stenosis: a case report","volume":"8","author":"Yamamoto","year":"2018","journal-title":"J. Orthop. Case Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14740338.2013.831403","article-title":"Adverse effects of golimumab in the treatment of rheumatologic diseases","volume":"13","author":"Yang","year":"2014","journal-title":"Expert Opin. drug Saf."},{"key":"B43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40360-024-00813-y","article-title":"Drug risks associated with sarcopenia: a real-world and gwas study","volume":"25","author":"Zhang","year":"2024","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2431587","article-title":"Pharmacovigilance insights into drug-induced cystitis: analysis of fda data from 2004 to 2024","author":"Zheng","year":"2024","journal-title":"Expert Opin. drug Saf."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1080\/09593330.2013.876450","article-title":"Estimation of parameter uncertainty for an activated sludge model using bayesian inference: a comparison with the frequentist method","volume":"35","author":"Zonta","year":"2014","journal-title":"Environ. Technol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1565480\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T07:19:28Z","timestamp":1742973568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1565480\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":45,"alternative-id":["10.3389\/fphar.2025.1565480"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1565480","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"article-number":"1565480"}}